Celil Alper USLUOĞULLARI, Eda DEMİR ÖNAL, Elif ÖZDEMİR, Sedat CANER, Osman ERSOY, Reyhan ERSOY, Bekir ÇAKIR

What is the effect of radioiodine therapy on Helicobacter pylori infection?

Helicobacter pylori is an important human pathogen associated with gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma. Radioiodine (RAI) treatment plays an important role in the management of differentiated thyroid cancer and primary hyperthyroidism. It is known that during RAI treatment, a considerable amount is absorbed by the stomach as well. In this study we aimed to reveal any therapeutic impact of RAI on H. pylori infections. Materials and methods: Eighty-seven patients who were hospitalized for RAI treatment were consecutively included in this study. Of those, 76 patients had differentiated thyroid cancer and 11 had primary hyperthyroidism. The urea breath test (UBT) was performed on the day before RAI, and the test was repeated after 2 months. Results: The dose of RAI was 115 ± 3.3 mCi (range: 100–150 mCi) in the patients with malignant disease and 22.7 ± 1.4 mCi (range: 20–30 mCi) in the remaining patients. Among the patients with differentiated thyroid cancer, 44 (57%) had positive and 32 (43%) had negative UBT tests prior to RAI. Four (36%) patients with hyperthyroidism had pretreatment positive UBT tests and 7 (64%) had negative tests. The results of UBT conducted 2 months after RAI therapy were identical in every patient, which means that none of the patients with positive UBT became UBT-negative (P = 1). Conclusion: RAI does not have any therapeutic effect on H. pylori infection.

Anahtar Kelimeler:

Key words: Helicobacter pylori, radioiodine therapy, differentiated thyroid cancer, urea breath test

What is the effect of radioiodine therapy on Helicobacter pylori infection?

Keywords:

Key words: Helicobacter pylori, radioiodine therapy, differentiated thyroid cancer, urea breath test,

PDF

___

Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449–490.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–1186.
Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306– 3
Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985–1001.
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668–3676.
Gurgul E, Sowinski J. Primary hyperthyroidism--diagnosis and treatment. Indications and contraindications for radioiodine therapy. Nucl Med Rev Cent East Eur 2011; 14: 29–32.
Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complimentary deoxyribonucleic acids from salivary gland, mammary gland and gastric mucosa. J Clin Endocrinol Metab 1998; 83: 1746–1751.
Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, Kirkwood ID, Gross MD. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000; 30: 115–132.
Gholamrezanezhad A, Mirpour S, Saghari M, Abdollahzadeh J, Pourmoslemi A, Yarmand S. Radio-iodine therapy and Helicobacter pylori infection. Ann Nucl Med 2008; 22: 917–920.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143– 11
Malfertheiner P, Megraud F, O’Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Juap B, Misiewicz JJ et al. Current European concepts in the management of helicobacter pylori infection. The Maastricht consensus report. The European Helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1–2.
Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–1384.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T et al. European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–664.
Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10: 157–171.
Frieri G, Pimpo MT, Palombieri A, Melideo D, Marcheggiano A, Caprilli R, D’Alessandro A, Seri S. Polyunsaturated fatty acid dietary supplementation: an adjuvant approach to treatment of Helicobacter pylori infection. Nutr Res 2000; 20: 907–916.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardi supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069–1079.
Huwez FU, Thirlwell D, Cockayne A, Ala’Aldeen DA. Mastic gum kills Helicobacter pylori. N Engl J Med 1998; 339: 1946.
Zhang HM, Wakisaka N, Maeda O, Yamamoto T. Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter. Cancer 1997; 80: 1897–903.
Hu FL. Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease. Zhonghua Yi Xue Za Zhi 1993; 73: 217–219.
Gaby AR. Helicobacter pylori eradication: are there alternatives to antibiotics? Altern Med Rev 2001; 6: 355–366.
Huysmans DAKC, Buijs WCAM, van de Ven MTP, van den Broek WJM, Kloppenborg PWC, Hermus ARMM, Corstens FHM. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J Nucl Med 1996; 37: 2072–2079.
Gholamrezanezhad A, Mirpour S, Ardekani JM, Bagheri M, Alimoghadam K, Yarmand S, Malekzadeh R. Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect. Nucl Med Commun 2009; 30: 210–216.